In the study cohort, 48.6% (101/208) of the study eyes were scheduled to anti-VEGF intravitreal treatment for wet age-related macular degeneration, 30.8% (64/208) for diabetic macular edema, 12% (25/208) for macular edema secondary to retinal vein occlusion, 4.8% (10/208) and 3.8% (8/208) for myopic choroidal neovascularization and proliferative diabetic retinopathy, respectively. This evidence concerns the gene VEGFA and diabetic macular edema.